Biomotion Sciences Warran... (SLXNW)
0.03
-0.01 (-32.58%)
At close: Jan 02, 2025, 9:00 PM
0.03
-0.40%
After-hours Jan 14, 2025, 05:04 PM EST
Company Description
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors.
The company engages in the treatment of solid tumors through its proprietary LODER delivery platform.
Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.
The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Biomotion Sciences Warrant
| Country | IL |
| IPO Date | n/a |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | n/a |
| CEO | Mirit Horenshtein Hadar |
Contact Details
Address: The Goldyne Savad Institute of Gene Therapy Jerusalem, IL | |
| Website | https://silexion.com |
Stock Details
| Ticker Symbol | SLXNW |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0002022416 |
| CUSIP Number | n/a |
| ISIN Number | KYG1281K1141 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Mirit Horenshtein Hadar | EVice President of Finance Affairs, Chief Financial Officer & Secretary |
| Dr. Mitchell Shirvan M.B.A., Ph.D. | Chief Scientific & Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 18, 2024 | 3 | Filing |
| Dec 17, 2024 | 8-K | Current Report |
| Dec 16, 2024 | 8-K | Current Report |
| Dec 10, 2024 | 424B3 | Filing |
| Dec 10, 2024 | 424B3 | Filing |
| Dec 10, 2024 | 8-K | Current Report |
| Nov 29, 2024 | 424B3 | Filing |
| Nov 29, 2024 | 424B3 | Filing |
| Nov 29, 2024 | 8-K | Current Report |
| Nov 27, 2024 | 8-K | Current Report |